viewOpen Orphan PLC

Open Orphan PLC targeting Q3 for profitability as it expands range of pharma and COVID-19 services

Proactive Research analyst Emma Ulker says Open Orphan PLC's (LON:ORPH) full year 2019 results reflect a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January.

Ulker says the outlook includes expanding its range of pharma services and completing the development of a COVID-19 HVC model which is already attracting the attention of the global pharma industry.

Click here to read Emma Ulker's latest update Open Orphan: Focused on a buoyant outlook

Quick facts: Open Orphan PLC

Price: 11.435 GBX

Market: AIM
Market Cap: £75.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan PLC: 'Rapidly scaling up and building out higher value, longer...

  Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services. She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the...

on 14/5/20

2 min read